Connection
David Camidge to Drug Combinations
This is a "connection" page, showing publications David Camidge has written about Drug Combinations.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.047 |
|
|
|
-
Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 10 10; 40(29):3383-3393.
Score: 0.047